Cargando…
Correction to: Gadoxetic acid‑enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502145/ https://www.ncbi.nlm.nih.gov/pubmed/34223963 http://dx.doi.org/10.1007/s00261-021-03155-z |
| _version_ | 1784580828457598976 |
|---|---|
| author | Elkilany, Aboelyazid Geisel, Dominik Müller, Tobias Fischer, Andreas Denecke, Timm |
| author_facet | Elkilany, Aboelyazid Geisel, Dominik Müller, Tobias Fischer, Andreas Denecke, Timm |
| author_sort | Elkilany, Aboelyazid |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8502145 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85021452021-10-22 Correction to: Gadoxetic acid‑enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression Elkilany, Aboelyazid Geisel, Dominik Müller, Tobias Fischer, Andreas Denecke, Timm Abdom Radiol (NY) Correction Springer US 2021-07-05 2021 /pmc/articles/PMC8502145/ /pubmed/34223963 http://dx.doi.org/10.1007/s00261-021-03155-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Elkilany, Aboelyazid Geisel, Dominik Müller, Tobias Fischer, Andreas Denecke, Timm Correction to: Gadoxetic acid‑enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression |
| title | Correction to: Gadoxetic acid‑enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression |
| title_full | Correction to: Gadoxetic acid‑enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression |
| title_fullStr | Correction to: Gadoxetic acid‑enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression |
| title_full_unstemmed | Correction to: Gadoxetic acid‑enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression |
| title_short | Correction to: Gadoxetic acid‑enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression |
| title_sort | correction to: gadoxetic acid‑enhanced mri in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502145/ https://www.ncbi.nlm.nih.gov/pubmed/34223963 http://dx.doi.org/10.1007/s00261-021-03155-z |
| work_keys_str_mv | AT elkilanyaboelyazid correctiontogadoxeticacidenhancedmriinprimarysclerosingcholangitisaddedvalueinassessingliverfunctionandmonitoringdiseaseprogression AT geiseldominik correctiontogadoxeticacidenhancedmriinprimarysclerosingcholangitisaddedvalueinassessingliverfunctionandmonitoringdiseaseprogression AT mullertobias correctiontogadoxeticacidenhancedmriinprimarysclerosingcholangitisaddedvalueinassessingliverfunctionandmonitoringdiseaseprogression AT fischerandreas correctiontogadoxeticacidenhancedmriinprimarysclerosingcholangitisaddedvalueinassessingliverfunctionandmonitoringdiseaseprogression AT denecketimm correctiontogadoxeticacidenhancedmriinprimarysclerosingcholangitisaddedvalueinassessingliverfunctionandmonitoringdiseaseprogression |